• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

IUBMB Life . Bacterial co-infections with SARS-CoV-2

tetano

Editor, Senior Moderator
IUBMB Life


. 2020 Aug 8.
doi: 10.1002/iub.2356. Online ahead of print.
Bacterial co-infections with SARS-CoV-2


Rasoul Mirzaei[SUP] 1 2 [/SUP], Pedram Goodarzi[SUP] 3 [/SUP], Muhammad Asadi[SUP] 4 [/SUP], Ayda Soltani[SUP] 5 [/SUP], Hussain Ali Abraham Aljanabi[SUP] 4 6 [/SUP], Ali Salimi Jeda[SUP] 7 [/SUP], Shirin Dashtbin[SUP] 8 [/SUP], Saba Jalalifar[SUP] 8 [/SUP], Rokhsareh Mohammadzadeh[SUP] 8 [/SUP], Ali Teimoori[SUP] 9 [/SUP], Kamran Tari[SUP] 2 10 [/SUP], Mehdi Salari[SUP] 2 10 [/SUP], Sima Ghiasvand[SUP] 1 [/SUP], Sima Kazemi[SUP] 1 [/SUP], Rasoul Yousefimashouf[SUP] 1 [/SUP], Hossein Keyvani[SUP] 7 [/SUP], Sajad Karampoor[SUP] 7 [/SUP]



Affiliations

Abstract

The pandemic coronavirus disease 2019 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), has affected millions of people worldwide. To date, there are no proven effective therapies for this virus. Efforts made to develop antiviral strategies for the treatment of COVID-19 are underway. Respiratory viral infections, such as influenza, predispose patients to co-infections and these lead to increased disease severity and mortality. Numerous types of antibiotics such as azithromycin have been employed for the prevention and treatment of bacterial co-infection and secondary bacterial infections in patients with a viral respiratory infection (e.g., SARS-CoV-2). Although antibiotics do not directly affect SARS-CoV-2, viral respiratory infections often result in bacterial pneumonia. It is possible that some patients die from bacterial co-infection rather than virus itself. To date, a considerable number of bacterial strains have been resistant to various antibiotics such as azithromycin, and the overuse could render those or other antibiotics even less effective. Therefore, bacterial co-infection and secondary bacterial infection are considered critical risk factors for the severity and mortality rates of COVID-19. Also, the antibiotic-resistant as a result of overusing must be considered. In this review, we will summarize the bacterial co-infection and secondary bacterial infection in some featured respiratory viral infections, especially COVID-19.

Keywords: COVID-19; SARS-CoV-2; antibiotic; bacterial co-infection; viral infection.
 
Back
Top Bottom